Weight Loss

On Thursday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S’ (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment for adults with obesity or overweight conditions linked to weight-related health issues. The...

AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies. The findings, presented at the 2026 Scientific Sessions of...

Eli Lilly and Co. (NYSE:LLY) on Sunday presented new analyses showing that women with obesity or overweight achieved significant weight loss with Foundayo across all stages of menopause. The findings were based on post-hoc analyses involving more than 1,500 women enrolled in the ATTAIN-1 and ATTAIN...

Novo Nordisk A/S (NYSE:NVO) on Monday presented results from its Phase 3 REIMAGINE 1-3 trials, showing that investigational treatment CagriSema significantly reduced both HbA1c and body weight in adults with Type 2 diabetes. The once-weekly therapy combines a novel amylin analog with a GLP-1...

Eli Lilly and Co. (NYSE:LLY) reported on Thursday topline results from its Phase 3 TRIUMPH-1 trial evaluating experimental obesity treatment retatrutide, with patients losing as much as 28.3% of body weight after 80 weeks of treatment. The study evaluated retatrutide, a triple hormone receptor...

President Donald Trump disclosed stock purchases worth as much as $680,000 in Eli Lilly & Co. (NYSE:LLY) earlier this year, with the trades occurring as federal agencies under his administration advanced policies that benefited the drugmaker's obesity drug business. Trump's Eli Lilly Purchases...

On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each....

Novo Nordisk A/S (NYSE:NVO) presented new analyses from its phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 in Istanbul, highlighting the long-term weight loss potential and functional benefits of its oral obesity treatment, Wegovy pill. The company said adults treated with...

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound. • Eli Lilly stock...

Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve substantial weight loss regardless of how quickly they initially responded to treatment. The...

WW International, Inc. (NASDAQ:WW) reported Thursday first-quarter fiscal 2026 revenue of $168.3 million, down 9.8% year over year from $186.6 million, but above the $158.6 million analyst estimate. • WW International shares are retreating from recent levels. What’s pressuring WW...

The Centers for Medicare & Medicaid Services announced that eligible Medicare beneficiaries living with obesity will gain access to Wegovy (semaglutide) for a $50 monthly copay beginning July 1, 2026, under the new Medicare GLP-1 Bridge program. The initiative, launched in partnership with Novo...

Eli Lilly and Co. (NYSE:LLY) shares climbed in Friday premarket trading after surging about 10% Thursday, fueled by stronger-than-expected first-quarter results and raised fiscal 2026 guidance. The drugmaker reported adjusted earnings of $8.55 per share, topping analyst estimates of $6.66, while...

Hims & Hers Health Inc. (NYSE:HIMS) said it is broadening access to FDA-approved weight loss treatments as shifting market dynamics around GLP-1 drugs drive demand for more flexible and affordable options. The company outlined a strategic shift in its U.S. weight loss business, emphasizing...

Novo Nordisk A/S (NYSE:NVO) reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide significantly improved blood sugar control in children and adolescents with type 2 diabetes. Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study...